José Luís
Zamorano Gómez
Catedrático/a de Universidad
Hôpital Européen Georges-Pompidou
París, FranciaPublications en collaboration avec des chercheurs de Hôpital Européen Georges-Pompidou (16)
2024
-
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC
European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 18-33
-
Tricuspid valve disease and cardiac implantable electronic devices
European Heart Journal, Vol. 45, Núm. 5, pp. 346-365
2021
-
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
Internal and Emergency Medicine, Vol. 16, Núm. 3, pp. 591-599
2020
-
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)
European Heart Journal, Vol. 41, Núm. 4, pp. 543-603
-
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
The Lancet, Vol. 396, Núm. 10266, pp. 1895-1904
-
Long-term outcomes of chronic coronary syndrome worldwide: Insights from the international CLARIFY registry
European Heart Journal, Vol. 41, Núm. 3, pp. 347-355
2019
-
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
European Respiratory Journal, Vol. 54, Núm. 3
2018
-
Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis
European Heart Journal, Vol. 39, Núm. 15, pp. 1224-1245
-
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy
Archives of Cardiovascular Diseases, Vol. 111, Núm. 2, pp. 74-84
2017
-
Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement
Journal of the American College of Cardiology, Vol. 69, Núm. 16, pp. 2067-2087
-
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF
Journal of the American College of Cardiology, Vol. 69, Núm. 4, pp. 409-419
2016
-
Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: Results from the PREFER in AF registry
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 2, Núm. 4, pp. 299-305
2014
-
Differences among western European countries in anticoagulation management of atrial fibrillation: Data from the PREFER IN AF Registry
Thrombosis and Haemostasis, Vol. 111, Núm. 5, pp. 833-841
-
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe
Heart, Vol. 100, Núm. 20, pp. 1625-1635
-
Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the PREvention of thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF)
Europace, Vol. 16, Núm. 1, pp. 6-14
2013
-
2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
European Heart Journal, Vol. 34, Núm. 28, pp. 2159-2219